Comments
Shilpa Medicare said on Wednesday that the US health regulator has issued an Establishment Inspection Report (EIR) for its manufacturing facilities at Raichur in Karnataka. The USFDA has issued the EIR for the company’s Active Pharmaceutical Ingredient manufacturing facilities, which were inspected between December 12 and 16, 2016. The inspection has now been closed by the USFDA, Shilpa Medicare said in a BSE filing. The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the Form 483 issued at the end of the inspection. The USFDA has reviewed the CAPA and has found it acceptable. Shares of Shilpa Medicare surged 5.3 per cent at ₹718.65 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.